The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma

Dimitrios Karantanis, Rathan M. Subramaniam, Patrick J. Peller, Val Lowe, Jolanta M. Durski, Douglas A. Collins, Evangelos Georgiou, Stephen Maxted Ansell, Gregory A. Wiseman

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: To our knowledge, there are no published data pertinent to the use of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma. Patients and Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied. PET/CT examinations were blindly reviewed by 2 experienced readers. The results were compared with the status of the disease, which was determined after evaluation of biopsy, laboratory, clinical and conventional imaging examination, and follow-up results. PET/CT results were thereby classified as true-positive, true-negative, false-positive, or false-negative. The degree of FDG uptake in the positive lesions was semiquantified using maximum standard uptake value (SUVmax). Results: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma. For nasal disease, PET/CT was true-positive in 5 cases, true-negative in 15 cases, and positive but unconfirmed in 1 case. For extranasal disease, PET/CT was true-positive in 3 cases, true-negative in 16 cases, and false-negative in 2 cases. The mean SUVmax in PET-positive lesions in nasal cavities or paranasal sinuses was 16 gm/mL (range, 5-25 gm/mL; median, 19.3 gm/mL). In extranasal disease, the mean SUVmax was 10.9 gm/mL (range, 4.6-34.1 gm/mL; median, 5.6 gm/mL). Conclusion: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic. PET/CT appears to be sensitive for the detection of disease in the nasopharynx and, to a lesser extent, in extranasal sites.

Original languageEnglish (US)
Pages (from-to)94-99
Number of pages6
JournalClinical Lymphoma and Myeloma
Volume8
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Fluorodeoxyglucose F18
Paranasal Sinuses
Nasopharyngeal Diseases
Nose Diseases
Positron Emission Tomography Computed Tomography
Nasal Cavity
Positron-Emission Tomography
Non-Hodgkin's Lymphoma
Biopsy

Keywords

  • FDG uptake
  • Nasal lesions
  • Neck nodes
  • Paranasal lesions

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. / Karantanis, Dimitrios; Subramaniam, Rathan M.; Peller, Patrick J.; Lowe, Val; Durski, Jolanta M.; Collins, Douglas A.; Georgiou, Evangelos; Ansell, Stephen Maxted; Wiseman, Gregory A.

In: Clinical Lymphoma and Myeloma, Vol. 8, No. 2, 04.2008, p. 94-99.

Research output: Contribution to journalArticle

Karantanis, Dimitrios ; Subramaniam, Rathan M. ; Peller, Patrick J. ; Lowe, Val ; Durski, Jolanta M. ; Collins, Douglas A. ; Georgiou, Evangelos ; Ansell, Stephen Maxted ; Wiseman, Gregory A. / The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. In: Clinical Lymphoma and Myeloma. 2008 ; Vol. 8, No. 2. pp. 94-99.
@article{6263dcfb551741b7ac2b20555510772d,
title = "The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma",
abstract = "Purpose: To our knowledge, there are no published data pertinent to the use of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma. Patients and Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied. PET/CT examinations were blindly reviewed by 2 experienced readers. The results were compared with the status of the disease, which was determined after evaluation of biopsy, laboratory, clinical and conventional imaging examination, and follow-up results. PET/CT results were thereby classified as true-positive, true-negative, false-positive, or false-negative. The degree of FDG uptake in the positive lesions was semiquantified using maximum standard uptake value (SUVmax). Results: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma. For nasal disease, PET/CT was true-positive in 5 cases, true-negative in 15 cases, and positive but unconfirmed in 1 case. For extranasal disease, PET/CT was true-positive in 3 cases, true-negative in 16 cases, and false-negative in 2 cases. The mean SUVmax in PET-positive lesions in nasal cavities or paranasal sinuses was 16 gm/mL (range, 5-25 gm/mL; median, 19.3 gm/mL). In extranasal disease, the mean SUVmax was 10.9 gm/mL (range, 4.6-34.1 gm/mL; median, 5.6 gm/mL). Conclusion: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic. PET/CT appears to be sensitive for the detection of disease in the nasopharynx and, to a lesser extent, in extranasal sites.",
keywords = "FDG uptake, Nasal lesions, Neck nodes, Paranasal lesions",
author = "Dimitrios Karantanis and Subramaniam, {Rathan M.} and Peller, {Patrick J.} and Val Lowe and Durski, {Jolanta M.} and Collins, {Douglas A.} and Evangelos Georgiou and Ansell, {Stephen Maxted} and Wiseman, {Gregory A.}",
year = "2008",
month = "4",
doi = "10.3816/CLM.2008.n.010",
language = "English (US)",
volume = "8",
pages = "94--99",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma

AU - Karantanis, Dimitrios

AU - Subramaniam, Rathan M.

AU - Peller, Patrick J.

AU - Lowe, Val

AU - Durski, Jolanta M.

AU - Collins, Douglas A.

AU - Georgiou, Evangelos

AU - Ansell, Stephen Maxted

AU - Wiseman, Gregory A.

PY - 2008/4

Y1 - 2008/4

N2 - Purpose: To our knowledge, there are no published data pertinent to the use of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma. Patients and Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied. PET/CT examinations were blindly reviewed by 2 experienced readers. The results were compared with the status of the disease, which was determined after evaluation of biopsy, laboratory, clinical and conventional imaging examination, and follow-up results. PET/CT results were thereby classified as true-positive, true-negative, false-positive, or false-negative. The degree of FDG uptake in the positive lesions was semiquantified using maximum standard uptake value (SUVmax). Results: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma. For nasal disease, PET/CT was true-positive in 5 cases, true-negative in 15 cases, and positive but unconfirmed in 1 case. For extranasal disease, PET/CT was true-positive in 3 cases, true-negative in 16 cases, and false-negative in 2 cases. The mean SUVmax in PET-positive lesions in nasal cavities or paranasal sinuses was 16 gm/mL (range, 5-25 gm/mL; median, 19.3 gm/mL). In extranasal disease, the mean SUVmax was 10.9 gm/mL (range, 4.6-34.1 gm/mL; median, 5.6 gm/mL). Conclusion: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic. PET/CT appears to be sensitive for the detection of disease in the nasopharynx and, to a lesser extent, in extranasal sites.

AB - Purpose: To our knowledge, there are no published data pertinent to the use of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma. Patients and Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied. PET/CT examinations were blindly reviewed by 2 experienced readers. The results were compared with the status of the disease, which was determined after evaluation of biopsy, laboratory, clinical and conventional imaging examination, and follow-up results. PET/CT results were thereby classified as true-positive, true-negative, false-positive, or false-negative. The degree of FDG uptake in the positive lesions was semiquantified using maximum standard uptake value (SUVmax). Results: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma. For nasal disease, PET/CT was true-positive in 5 cases, true-negative in 15 cases, and positive but unconfirmed in 1 case. For extranasal disease, PET/CT was true-positive in 3 cases, true-negative in 16 cases, and false-negative in 2 cases. The mean SUVmax in PET-positive lesions in nasal cavities or paranasal sinuses was 16 gm/mL (range, 5-25 gm/mL; median, 19.3 gm/mL). In extranasal disease, the mean SUVmax was 10.9 gm/mL (range, 4.6-34.1 gm/mL; median, 5.6 gm/mL). Conclusion: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic. PET/CT appears to be sensitive for the detection of disease in the nasopharynx and, to a lesser extent, in extranasal sites.

KW - FDG uptake

KW - Nasal lesions

KW - Neck nodes

KW - Paranasal lesions

UR - http://www.scopus.com/inward/record.url?scp=44649171004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649171004&partnerID=8YFLogxK

U2 - 10.3816/CLM.2008.n.010

DO - 10.3816/CLM.2008.n.010

M3 - Article

C2 - 18501102

AN - SCOPUS:44649171004

VL - 8

SP - 94

EP - 99

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -